ClariVest Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

ClariVest Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3	Closed	–	–	746
2021 Q1	$0	Hold	3	–	–	﹤0.01%	741
2020 Q4	$0	Hold	3	–	–	﹤0.01%	759
2020 Q3	$0	Hold	3	–	–	﹤0.01%	757
2020 Q2	$0	Hold	3	–	–	﹤0.01%	783
2020 Q1	$0	Hold	3	–	–	﹤0.01%	689
2019 Q4	$0	Hold	3	–	–	﹤0.01%	652
2019 Q3	$0	Hold	3	–	–	﹤0.01%	672
2019 Q2	$0	Hold	3	–	–	﹤0.01%	654
2019 Q1	$0	Hold	3	–	–	﹤0.01%	713
2018 Q4	$0	Hold	3	–	–	﹤0.01%	701
2018 Q3	$0	Hold	3	–	–	﹤0.01%	724
2018 Q2	$0	Hold	3	–	–	﹤0.01%	722
2018 Q1	$0	Hold	3	–	–	﹤0.01%	726
2017 Q4	$0	Sell	3 -7	-70%	-$609	﹤0.01%	714
2017 Q3	$1K	Hold	10	–	–	﹤0.01%	584
2017 Q2	$1K	Hold	10	–	–	﹤0.01%	600
2017 Q1	$1K	Hold	10	–	–	﹤0.01%	622
2016 Q4	$1K	Hold	10	–	–	﹤0.01%	604
2016 Q3	$1K	Hold	10	–	–	﹤0.01%	630
2016 Q2	$1K	Buy	10 +5	+100%	+$425	﹤0.01%	579
2016 Q1	$0	Hold	5	–	–	﹤0.01%	628
2015 Q4	$1K	Hold	5	–	–	﹤0.01%	573
2015 Q3	$1K	Buy	+5	New	+$668	﹤0.01%	548

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

ClariVest Asset Management's BMRN Position: Q2 2021 in Review

ClariVest Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2021, closing a stake of 3 shares.

ClariVest Asset Management first reported a position in BMRN in Q3 2015 and held it in 23 quarters. The position peaked at $1K in Q3 2017. 531 funds tracked by Wall St. Rank hold BMRN as of Q2 2021.

ClariVest Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
ClariVest Asset Management sold 3 BioMarin Pharmaceuticals shares in Q2 2021.
ClariVest Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2015 and held it in 23 quarters.
ClariVest Asset Management's BioMarin Pharmaceuticals position peaked at $1K in Q3 2017.
531 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2021.

Based on ClariVest Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.